Sanuwave Health, Inc. reported second quarter 2026 financial results with revenue of $9.7 million, a 3% decline from the prior year period. Gross margin decreased to 76.2% from 78.1%, and GAAP operating income turned to a loss of $(0.3) million compared to $1.4 million previously. The company withdrew its fiscal year 2026 financial guidance due to uncertainty surrounding CMS reimbursement changes for wound care treatments. System sales declined to 82 units from 116 in the prior year, while applicator revenue grew 13% to $7.3 million. Sanuwave operates in the medical device industry, specializing in FDA-cleared regenerative medicine and wound care products.
